Novartis says experimental drug helps chronic migraine sufferers

ZURICH, Sept 16 (Reuters) - About 40 percent of chronic

migraine sufferers taking an experimental drug developed by

Novartis and Amgen saw the number of days they

suffered a migraine cut by at least half, beating the placebo in

the trial.

Read more